B Eiben1, M Krapp2, H Borth3, N Kutur4, P Kreiselmaier5, R Glaubitz6, J Deutinger7, E Merz8. 1. Institut für Klinische Genetik Nordrhein, Essen, Germany. 2. amedes Hamburg, Zentrum für Endokrinologie, Kinderwunsch und Pränatale Medizin, Hamburg, Germany. 3. Genetic Department, amedes Institut f. Labormedizin und Klinische Genetik Institut f. Labormedizin und Klinische Genetik Rhein/ Ruhr MVZ GmbH, Essen, Germany. 4. Genetic Department, amedes Institut f. Labormedizin und Klinische Genetik Rhein/ Ruhr MVZ GmbH, Essen, Germany. 5. MVZ FCH, amedes Hamburg, Zentrum für Pränatale Medizin, Hamburg, Germany. 6. amedes Labor, Human Genetics, Hannover, Germany. 7. UFK Wien, Dep. for Prenatal Diagnostic and Therapy, Wien, Austria. 8. KH Nordwest, Obstetrics & Gynecology, Frankfurt/Main, Germany.
Abstract
BACKGROUND & PATIENT: Data from 3 008 patients, who underwent single-nucleotide-polymorphism (SNP)-based noninvasive prenatal testing (NIPT) are presented. METHOD: The PanoramaTM test (Natera, San Carlos, CA) was used to analyze cell-free fetal DNA from maternal blood for trisomies 21, 18, and 13, triploidy and sex-chromosome aneuploidies. RESULT: In 2 942 (97.8%) cases, a result was obtained. The average fetal fraction was 10.2%. A high-risk result for fetal aneuploidy was made for 65 (2.2%) cases. In 59 (90.8%) of these cases, invasive testing confirmed the aneuploidy. There were 6 false-positive cases. In the false-positive group, the fetal fraction was significantly lower. The overall positive predictive value was 90.8%. No false-negative cases were reported but many patients in this study have not delivered yet. Therefore, exact data cannot be given for potential false-negative cases. CONCLUSION: SNP-based NIPT is a reliable screening method for evaluating the risk of aneuploidies of chromosomes 21, 18 and 13. By using NIPT, the number of invasive procedures may be reduced significantly compared to maternal age and first-trimester screening.
BACKGROUND & PATIENT: Data from 3 008 patients, who underwent single-nucleotide-polymorphism (SNP)-based noninvasive prenatal testing (NIPT) are presented. METHOD: The PanoramaTM test (Natera, San Carlos, CA) was used to analyze cell-free fetal DNA from maternal blood for trisomies 21, 18, and 13, triploidy and sex-chromosome aneuploidies. RESULT: In 2 942 (97.8%) cases, a result was obtained. The average fetal fraction was 10.2%. A high-risk result for fetal aneuploidy was made for 65 (2.2%) cases. In 59 (90.8%) of these cases, invasive testing confirmed the aneuploidy. There were 6 false-positive cases. In the false-positive group, the fetal fraction was significantly lower. The overall positive predictive value was 90.8%. No false-negative cases were reported but many patients in this study have not delivered yet. Therefore, exact data cannot be given for potential false-negative cases. CONCLUSION: SNP-based NIPT is a reliable screening method for evaluating the risk of aneuploidies of chromosomes 21, 18 and 13. By using NIPT, the number of invasive procedures may be reduced significantly compared to maternal age and first-trimester screening.
Entities:
Keywords:
chromosomal aberration; down syndrome; laboratory tests; pregnancy; screening
Authors: Kypros H Nicolaides; Argyro Syngelaki; Maria del Mar Gil; Maria Soledad Quezada; Yana Zinevich Journal: Fetal Diagn Ther Date: 2013-10-10 Impact factor: 2.587
Authors: Michael T Mennuti; Athena M Cherry; Jennifer J D Morrissette; Lorraine Dugoff Journal: Am J Obstet Gynecol Date: 2013-03-22 Impact factor: 8.661
Authors: L J Salomon; Z Alfirevic; F Audibert; K O Kagan; Dario Paladini; G Yeo; N Raine-Fenning Journal: Ultrasound Obstet Gynecol Date: 2014-06-03 Impact factor: 7.299
Authors: Diana W Bianchi; R Lamar Parker; Jeffrey Wentworth; Rajeevi Madankumar; Craig Saffer; Anita F Das; Joseph A Craig; Darya I Chudova; Patricia L Devers; Keith W Jones; Kelly Oliver; Richard P Rava; Amy J Sehnert Journal: N Engl J Med Date: 2014-02-27 Impact factor: 91.245
Authors: Andrew B Sparks; Eric T Wang; Craig A Struble; Wade Barrett; Renee Stokowski; Celeste McBride; Jacob Zahn; Kevin Lee; Naiping Shen; Jigna Doshi; Michel Sun; Jill Garrison; Jay Sandler; Desiree Hollemon; Patrick Pattee; Aoy Tomita-Mitchell; Michael Mitchell; John Stuelpnagel; Ken Song; Arnold Oliphant Journal: Prenat Diagn Date: 2012-01-06 Impact factor: 3.050
Authors: Glenn E Palomaki; Cosmin Deciu; Edward M Kloza; Geralyn M Lambert-Messerlian; James E Haddow; Louis M Neveux; Mathias Ehrich; Dirk van den Boom; Allan T Bombard; Wayne W Grody; Stanley F Nelson; Jacob A Canick Journal: Genet Med Date: 2012-02-02 Impact factor: 8.822
Authors: Matthew S Hestand; Mark Bessem; Peter van Rijn; Renee X de Menezes; Daoud Sie; Ingrid Bakker; Elles M J Boon; Erik A Sistermans; Marjan M Weiss Journal: Eur J Hum Genet Date: 2018-09-25 Impact factor: 4.246